When used for evil, they can wreak global havoc of exactly the kind we are now fighting. That is why many people, myself included, have advocated for a moratorium on human gene editing. But not just a moratorium: There should have been international treaties to prevent the use of CRISPR for gene editing on humans or animals.
The U. But none of this happened, nor were there any other checks and balances. It is now too late to stop the global spread of these technologies—the genie is out of the bottle.
Now, the only solution is to accelerate the good side of these technologies while building our defenses. In the past, vaccines took decades to create. Now, we are on track to have them within months, thanks to advances in genetic engineering. It is conceivable that this could be reduced to hours once the technologies are perfected. We must treat the coronavirus pandemic as a full dress rehearsal of what is to come, including viruses deliberately engineered by humans.
We can also accelerate the process of testing vaccines and treatments, which has become the slowest part of the development cycle. The leading company in this field, SEngine Precision Medicine , is able to test more than drugs on these organoids, removing the need to use human subjects as the guinea pigs. Engineers at the Massachusetts Institute of Technology have been developing a microfluidic platform that connects engineered tissues from up to 10 organs, allowing the replication of human-organ interactions for weeks at a time in order to measure the effects of drugs on different parts of the body.
Many more such systems are being developed that could accelerate testing and treatment. All these technologies will greatly strengthen our biodefense. Sign up for email notifications and we'll let you know about new publications in your areas of interest when they're released. Get This Book. Visit NAP. Looking for other ways to read this? No thanks. Suggested Citation: "Genetic engineering of viruses and of virus vectors: A preface.
Genetic engineering of viruses and of virus vectors: A preface. Page Share Cite. Login or Register to save! He says his work is necessary to explore what bioterrorists might do.
But the research brings closer the prospect of pox viruses that cause only mild infections in humans being turned into diseases lethal even to people who have been vaccinated. And vaccines are currently our main defence against smallpox and its relatives, such as the monkeypox that reached the US this year. Some researchers think the latest research is risky and unnecessary.
Ramshaw was a member of the team that accidentally discovered how to make mousepox more deadly New Scientist , 13 January Since then, Ramshaw told New Scientist , his team has also created more deadly forms of mousepox, and has used the same method to engineer a more deadly rabbitpox virus. But this research revealed that the modified pox viruses are not contagious, he says. That is good news in the sense that these viruses could not cause ecological havoc by wiping out mouse or rabbit populations around the world if they escaped from a lab.
Kastenmuller, W. Dendritic cell-targeted vaccines—hope or hype? Kaur, T. Immunocompatibility of bacteriophages as nanomedicines. Kilcher, S. Engineering bacteriophages as versatile biologics. Cross-genus rebooting of custom-made, synthetic bacteriophage genomes in L-form bacteria. USA , — Kirby, A. Synergistic action of gentamicin and bacteriophage in a continuous culture population of Staphylococcus aureus.
PLoS One 7:e Kiro, R. RNA Biol. Knott, G. Koonin, E. Kortright, K. Phage therapy: a renewed approach to combat antibiotic-resistant bacteria.
Cell Host Microbe 25, — Kutter, E. Phage therapy in clinical practice: treatment of human infections. Lemay, M. Lemire, S. Phage-based applications in synthetic biology. Li, W. Peptide vaccine: progress and challenges. Vaccines 2, — Li, Q. Assembly of the small outer capsid protein, Soc, on bacteriophage T4: a novel system for high density display of multiple large anthrax toxins and foreign proteins on phage capsid.
Link, A. Innate immunity mediates follicular transport of particulate but not soluble protein antigen. Low, J. Safety and immunogenicity of a virus-like particle pandemic influenza A H1N1 vaccine: results from a double-blinded, randomized phase I clinical trial in healthy Asian volunteers.
Vaccine 32, — Lu, T. Dispersing biofilms with engineered enzymatic bacteriophage. The next generation of bacteriophage therapy. Maciejewska, B. Applications of bacteriophages versus phage enzymes to combat and cure bacterial infections: an ambitious and also a realistic application? Macri, C. Targeting dendritic cells: a promising strategy to improve vaccine effectiveness. Mahichi, F. Site-specific recombination of T2 phage using IP long tail fiber genes provides a targeted method for expanding host range while retaining lytic activity.
FEMS Microbiol. Mamedov, T. Rational de novo gene synthesis by rapid polymerase chain assembly PCA and expression of endothelial protein-C and thrombin receptor genes. Mantegazza, A.
Traffic 14, — Marinelli, L. Recombineering: a powerful tool for modification of bacteriophage genomes. Bacteriophage 2, 5— BRED: a simple and powerful tool for constructing mutant and recombinant bacteriophage genomes. PLoS One 3:e Martel, B. Marzari, R. Extending filamentous phage host range by the grafting of a heterologous receptor binding domain. Gene , 27— Miedzybrodzki, R. Clinical aspects of phage therapy. Moelling, K. A wake-up call: we need phage therapy now. Murphy, K. Phage recombinases and their applications.
Nafissi, N. Bacteriophage recombination systems and biotechnical applications. Namura, M. Detection of Escherichia coli with fluorescent labeled phages that have a broad host range to E. National Institute of Allergy and Infectious Diseases Nicastro, J. Bacteriophage lambda display systems: developments and applications. Nobrega, F. Revisiting phage therapy: new applications for old resources.
Targeting mechanisms of tailed bacteriophages. Oda, M. Rapid detection of Escherichia coli OH7 by using green fluorescent protein-labeled PP01 bacteriophage. Oppenheim, A. In vivo recombineering of bacteriophage lambda by PCR fragments and single-strand oligonucleotides.
Pan, Y. Klebsiella phage PhiK encodes multiple depolymerases for multiple host capsular types. Pawluk, A. Pei, R. Inhibition of biofilm formation by T7 bacteriophages producing quorum-quenching enzymes. Pires, D. Genetically engineered phages: a review of advances over the last decade. Pirnay, J.
The magistral phage. Poteete, A. What makes the bacteriophage lambda red system useful for genetic engineering: molecular mechanism and biological function. Rao, V. Salmond, G. A century of the phage: past, present and future.
Samson, J. Revenge of the phages: defeating bacterial defences. Sarkis, G. L5 luciferase reporter mycobacteriophages: a sensitive tool for the detection and assay of live mycobacteria.
Sartorius, R. Vaccination with filamentous bacteriophages targeting DEC induces DC maturation and potent anti-tumor T-cell responses in the absence of adjuvants.
Antigen delivery by filamentous bacteriophage fd displaying an anti-DEC single-chain variable fragment confers adjuvanticity by triggering a TLR9-mediated immune response.
EMBO Mol. Sathaliyawala, T. Assembly of human immunodeficiency virus HIV antigens on bacteriophage T4: a novel in vitro approach to construct multicomponent HIV vaccines.
Schilling, T. Schooley, R. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Agents Chemother. Seed, K. Battling phages: how bacteria defend against viral attack. PLoS Pathog. Shang, Y. Construction and rescue of a functional synthetic baculovirus. Shen, J. Shepardson, K. Induction of antiviral immune response through recognition of the repeating subunit pattern of viral capsids is toll-like receptor 2 dependent.
MBio 8, pii: e Shivachandra, S. Multicomponent anthrax toxin display and delivery using bacteriophage T4. Vaccine 25, — Shmakov, S.
Smith, H. III, Pfannkoch, C.
0コメント